Blastic Plasmacytoid Dendritic Cell Neoplasm research hub
5 indexed studies · 2 currently recruiting
- active not recruitingPHASE1, PHASE2
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
This study is testing a new medicine called IMGN632 for people with certain types of blood cancers, including a rare one called BPDCN. We're looking at how safe it is, how well it's tolerated, and if it helps fight the cancer.
United States · France · Germany - active not recruitingPHASE1
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
This study looks at a new drug, navitoclax, alone or with an existing drug, ruxolitinib, for a group of blood cancers called myeloproliferative neoplasms. Researchers want to see if it's safe, how the body handles it, and if it affects other drugs.
United States · Belgium · Bulgaria - active not recruitingPHASE1
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
This study looks at a new drug, INCB057643, for people with certain blood cancers like myelofibrosis. It checks if the drug is safe, what dose works best, and if it helps by itself or when given with another medicine called ruxolitinib.
United States · Canada · China - recruiting
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
This study looks at how your body's 'biological age' (not just your birth age) might affect health problems in people with certain blood cancers called Myeloproliferative Neoplasms (MPNs). We want to see if this biological age can predict complications like blood clots or the disease getting worse.
France - recruiting
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
This study looks at why some people with certain blood conditions don't respond to their first treatments. We're hoping to find clues in their genes and other markers to better predict who needs different medicines from the start. This could lead to more personalised care.
France